-25% en todo – hasta el 31 de octubreEnvío gratis en pedidos desde $99
Steroidify

Uso del producto: Este producto está destinado exclusivamente a la investigación.

Toda la información de los productos de este sitio web tiene fines exclusivamente educativos. Cualquier forma de introducción en el cuerpo de personas o animales está estrictamente prohibida por la ley. Este producto solo debe ser manipulado por profesionales autorizados y cualificados. No es un medicamento, alimento ni cosmético y no debe etiquetarse, utilizarse ni presentarse como tal.

Nebivolol 300 mg (5 mg / 60 capsules)

Nebivolol is a third-generation β-adrenoceptor blocker with high β1-selectivity and a unique secondary mechanism: activation of endothelial nitric oxide synthase (eNOS) via GRK/β-arrestin biased agonism, producing vasodilation absent from earlier-generation β-blockers.

Cantidad
El precio original era: $39.95.El precio actual es: $29.96.
Ver informes publicados
La misma fórmula de confianza. Nuevo diseño.

Durante el cambio de envase, puedes recibir productos con la etiqueta anterior o con la nueva. La formulación, la pureza y la calidad siguen siendo exactamente las mismas, según nuestros estándares.

Métodos de pago aceptados
  • Tarjeta de crédito
  • Transferencia bancaria (SEPA inmediata)
  • Transferencia bancaria (ACH)
  • Wise
  • Revolut
  • Zelle
  • Remitly
  • Western Union
  • Chime
  • Otros

-25% en todo – hasta el 31 de octubre
25% sobre los precios habituales, en sustitución de otras ofertas. Acumulable solo con el descuento crypto.

Envío

Envío en el día para pedidos en EE. UU. realizados antes de las 12:00 EST.

Ver la política de envíos →
Devoluciones

Devoluciones sin complicaciones en 30 días para productos sin abrir.

Ver la política de devoluciones →
Analizado en laboratorio

Cada lote se analiza para comprobar su pureza, potencia y calidad.

Ver resultados de laboratorio →
Atención al cliente

¿Tienes alguna pregunta? Escríbenos por Telegram.

Abrir el chat →

Nebivolol is a third-generation β-adrenoceptor blocker with high β1-selectivity and a unique secondary mechanism: activation of endothelial nitric oxide synthase (eNOS) via GRK/β-arrestin biased agonism, producing vasodilation absent from earlier-generation β-blockers. Research applications include β1-AR pharmacology, biased agonism at β-adrenoceptors, eNOS activation pathway investigation, and NO-mediated vascular biology research.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

3D Molecular Structure

Drag to rotate · scroll to zoom
Loading 3D structure…
Chemical Formula C22H25F2NO4
Synonyms Bystolic (trade name), Nebilet (trade name), Nebivololum
Molar Mass 405.44 g/mol
CAS Number 99200-09-06
PubChem CID 71301
Total Compound Content 300 mg (5 mg per capsule)
Shelf Life 36 months
Nebivolol is a difluoro-chroman-based β1-selective adrenoceptor antagonist with approximately 290-fold selectivity for β1 over β2-AR. What distinguishes nebivolol pharmacologically from earlier β-blockers is its concurrent eNOS activation via a GRK2/β-arrestin biased signalling pathway at β2-AR — a G protein-independent mechanism that activates eNOS/NO/cGMP vasodilation independent of Gsα. This biased agonism at β2-AR (producing vasodilation) combined with β1-AR antagonism (reducing cardiac output) creates a haemodynamic profile that differentiates nebivolol from carvedilol, metoprolol, and atenolol. Nebivolol is a racemate — the SRRR enantiomer is primarily responsible for β1 antagonism, while the RSSS enantiomer potentiates antihypertensive effects via eNOS pathway. CYP2D6 polymorphisms significantly affect nebivolol metabolism, with poor metabolisers having substantially higher plasma exposure — an important variable in pharmacogenomic research designs. Half-life 12–19 hours. Supplied in 5 mg capsules. Independently third-party HPLC-tested; COA available per batch.

Every batch is independently lab tested for identity, purity and potency. View our lab testing program →

What is the GRK/β-arrestin biased agonism mechanism that distinguishes nebivolol from other β-blockers?

Most β-blockers are Gα antagonists — they block Gsα-coupled cAMP signalling at β-ARs without activating alternative pathways.

Nebivolol is also a GRK2/β-arrestin biased agonist at β2-AR: it activates GRK2-mediated receptor phosphorylation and β-arrestin recruitment without activating Gsα. β-arrestin then scaffolds EGFR transactivation and ERK1/2 phosphorylation cascades that activate eNOS and promote NO production.

This G protein-independent, β-arrestin-dependent signalling produces vasodilation that is absent from pure Gα-antagonist β-blockers. This biased agonism mechanism is also documented for carvedilol and represents an active area of β-AR pharmacology research.

How does nebivolol's eNOS activation differ mechanistically from direct NO donors in vascular research?

Direct NO donors (nitroprusside, SNAP, DETA-NONOate) deliver exogenous NO or spontaneously release it, bypassing eNOS entirely. Nebivolol activates endogenous eNOS via β-arrestin/EGFR/Akt signalling, producing NO through the physiological L-arginine/NOS pathway in vascular endothelial cells.

This eNOS-dependent NO production is subject to normal substrate availability, NOS regulation, and shear stress modulation — making nebivolol relevant to studies examining endogenous NO pathway activation versus exogenous NO supplementation. The eNOS pathway activation also produces BH4-dependent effects on NOS coupling that differ from uncoupled exogenous NO delivery.

How do CYP2D6 polymorphisms affect nebivolol pharmacokinetics in research studies?

Nebivolol is predominantly metabolised by CYP2D6 via hydroxylation and glucuronidation. CYP2D6 poor metabolisers (approximately 7–10% of Caucasian populations, 2% of Asians) have significantly higher nebivolol plasma exposure and longer effective half-life compared to extensive metabolisers.

In pharmacogenomic research designs, CYP2D6 genotyping of experimental subjects is important for interpreting interindividual variation in nebivolol PK/PD relationships. This CYP2D6 dependence is shared by several β-blockers (metoprolol, carvedilol) but not others (atenolol, bisoprolol), making nebivolol useful in comparative CYP2D6-dependent versus independent β-blocker metabolism studies.

Customer Reviews (6)

★★★★★ ★★★★★
5 / 5
5★
6
4★
0
3★
0
2★
0
1★
0
★★★★★ ★★★★★
Verified Buyer
Lupe

Easy, fast, great...good quality

★★★★★ ★★★★★
Verified Buyer
Ward

FRAG is great. Good quality and very fast shipping.

★★★★★ ★★★★★
Verified Buyer
Cassy

I received my package in a timely manner and appreciate the kind customer service and care!! Steroidify IS A HONEST WEBSITE. Will order again!

★★★★★ ★★★★★
Verified Buyer
Tommy N.

Great Product! Good Price! Fast Delivery! Doesn't get any better.

★★★★★ ★★★★★
Verified Buyer
Ella

Surpasses all competitors—best product ever.